CJC-1295 (no DAC)
Mod GRF 1-29 / Modified GRF
CJC-1295 (without DAC) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of amino acids 1-29 of GHRH with amino acid substitutions to increase stability and receptor binding affinity. Also known as Modified GRF(1-29) or Mod GRF, it produces pulsatile growth hormone release that more closely mimics natural physiology compared to the DAC variant. It is most commonly combined with a GHRP such as Ipamorelin to amplify GH output through dual-pathway stimulation.
作用机制
Modified growth hormone releasing hormone (GHRH) analog with amino acid substitutions at positions 2, 8, 15, and 27 to prevent enzymatic degradation. Stimulates pituitary GHRH receptors to amplify natural GH pulses without extending the pulse duration.
研究协议
仅供研究使用,非医疗建议。
Research protocols use 100-200mcg 2-3 times daily via subcutaneous injection, typically combined with a GHRP (ipamorelin, GHRP-2, or GHRP-6). Administer on empty stomach 30 min before or 2 hours after meals.
研究笔记
Clinical Research Status
CJC-1295 without DAC has been studied in clinical trials demonstrating dose-dependent increases in GH and IGF-1 levels. The no-DAC version has a short half-life of approximately 30 minutes, requiring more frequent dosing but producing GH pulses rather than sustained elevation. No FDA approval exists for any indication; it remains an investigational compound available through research suppliers.
Key Published Findings
Clinical studies show that Modified GRF(1-29) increases GH secretion 2-10 fold when administered subcutaneously. Combination with GHRPs produces synergistic effects, with GH output greater than either compound alone. Research demonstrates improvements in body composition, sleep quality, and recovery markers in study participants over 4-12 week protocols.
Safety Profile
Side effects are generally mild and include transient flushing, headache, dizziness, and injection site reactions. Unlike exogenous GH, it preserves the hypothalamic-pituitary feedback loop, reducing risk of GH excess. Water retention and joint stiffness may occur at higher doses, consistent with elevated IGF-1 levels.
Drug Interactions & Contraindications
Should not be combined with somatostatin analogs (e.g., octreotide) which directly oppose its mechanism. Caution advised with glucocorticoids which suppress the GH axis. Contraindicated in individuals with active malignancy due to IGF-1's proliferative effects on certain cancer types.
Comparison to Related Compounds
The no-DAC version produces a short GH pulse (~30 min half-life) versus CJC-1295 with DAC which elevates GH for 6-8 days due to albumin binding. Most practitioners prefer no-DAC for its more physiological pulsatile pattern and lower risk of prolonged IGF-1 elevation. Sermorelin is an older, less potent GHRH analog that CJC-1295 has largely replaced in research settings.
Community Observations
Typically dosed at 100-300mcg subcutaneously 1-3 times daily, most commonly before bed and upon waking. The combination of Mod GRF + Ipamorelin at 100mcg each is considered the standard research protocol for GH optimization. Users report improved sleep quality, faster recovery, and gradual improvements in body composition over 3-6 month protocols.
半衰期
~30 minutes
复溶
Bacteriostatic water (BAC)
存储
冻干
Refrigerate 2-8C up to 18 months.
复溶后
Refrigerate 2-8C. Use within 14 days.
美国法律状态
又称作
常见问题
什么是 CJC-1295 (no DAC)?
CJC-1295 (without DAC) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of amino acids 1-29 of GHRH with amino acid substitutions to increase stability and receptor binding affinity. Also known as Modified GRF(1-29) or Mod GRF, it produces pulsatile growth hormone release that more closely mimics natural physiology compared to the DAC variant. It is most commonly combined with a GHRP such as Ipamorelin to amplify GH output through dual-pathway stimulation.
CJC-1295 (no DAC) 如何起作用?
Modified growth hormone releasing hormone (GHRH) analog with amino acid substitutions at positions 2, 8, 15, and 27 to prevent enzymatic degradation. Stimulates pituitary GHRH receptors to amplify natural GH pulses without extending the pulse duration.
CJC-1295 (no DAC) 在美国的监管状态是什么?
Research chemical (not FDA-approved)
CJC-1295 (no DAC) 的半衰期是多少?
~30 minutes
CJC-1295 (no DAC) 还有哪些名称?
Mod GRF 1-29, Modified GRF
Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。
阅读完整免责声明